A number of firms have modified their ratings and price targets on shares of Connect Biopharma (NASDAQ: CNTB) recently:
- 7/9/2026 – Connect Biopharma is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $8.00 price target on the stock.
- 6/30/2026 – Connect Biopharma was downgraded by Weiss Ratings from “sell (d)” to “sell (d-)”.
- 6/28/2026 – Connect Biopharma was downgraded by Wall Street Zen from “hold” to “sell”.
- 6/26/2026 – Connect Biopharma is now covered by Piper Sandler. They set an “overweight” rating and a $7.00 price target on the stock.
- 6/26/2026 – Connect Biopharma is now covered by Piper Sandler. They set an “overweight” rating and a $7.00 price target on the stock.
- 6/25/2026 – Connect Biopharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $7.00 price target on the stock.
- 6/20/2026 – Connect Biopharma was upgraded by Wall Street Zen from “sell” to “hold”.
- 6/18/2026 – Connect Biopharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $7.00 price target on the stock.
- 5/26/2026 – Connect Biopharma is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $6.00 price target on the stock.
- 5/26/2026 – Connect Biopharma is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $6.00 price target on the stock.
- 5/21/2026 – Connect Biopharma is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $4.00 price target on the stock.
- 5/21/2026 – Connect Biopharma is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $4.00 price target on the stock.
Insider Transactions at Connect Biopharma
In other news, Director James Huang acquired 150,000 shares of the firm’s stock in a transaction on Friday, May 29th. The shares were purchased at an average cost of $2.48 per share, with a total value of $372,000.00. Following the acquisition, the director directly owned 13,310,000 shares in the company, valued at $33,008,800. This represents a 1.14% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 22.60% of the stock is owned by company insiders.
The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.
See Also
- Five stocks we like better than Connect Biopharma
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for Connect Biopharma Holdings Limited Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma Holdings Limited Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
